Hematologic Paraneoplastic Syndrome in Newly Diagnosed Patients with Lung Cancer
Downloads
Introduction: Lung cancer could have signs and symptoms generated by paraneoplastic syndromes. This study aimed to describe and analyze hematologic paraneoplastic syndrome in patients with lung cancer in Indonesia.
Methods: This was a cross-sectional analytic study conducted in Persahabatan National Respiratory Referral Hospital, Jakarta, between September 2018 and February 2019, on all newly diagnosed patients with lung cancer whose diagnosis was established and who fulfilled the inclusion and exclusion criteria.
Results: The mean age of subjects was 56.7 ± 11.4 years old. Most subjects were male, had normal nutritional status (42.6%), had a smoking history (75%), and had a moderate Brinkman Index (BI) value (52%). The most common type of histology was squamous cell carcinoma (SCC) (39.7%), with advanced stage (83.8%) and performance status <2 (94.1%). Paraneoplastic anemia was 40.4%, associated with poor nutritional status and commonly normocytic normochromic anemia. The proportion of paraneoplastic leukocytosis was 39%, associated with males and smoking history. The proportion of paraneoplastic neutrophilia was 51.5%, and it was related to males, smoking history, and SCC histology type. Paraneoplastic hypereosinophilia and thrombocytosis proportions were 2.9% and 18.4%, respectively. The proportion of paraneoplastic hypercoagulability was 91.2%, which was caused by the elevated D-dimer level.
Conclusion: The most common hematologic paraneoplastic syndromes in patients with lung cancer were hypercoagulability, neutrophilia, and anemia. The low hemoglobin (Hb) level of paraneoplastic anemia was associated with low body mass index (BMI). Male and smoking history in lung cancer patients were associated with paraneoplastic leukocytosis and/or neutrophilia.
Jusuf A, Yahya W, Hermansyah E. Epidemiologi Kanker Paru. In: Jusuf A (ed) Dasar-Dasar Diagnosis Kanker Paru. Jakarta: UI Press, 2017, pp. 1–9.
Jusuf A, Hudoyo A, Andriani R, et al. Diagnosis Kanker Paru. In: Jusuf A (ed) Dasar-Dasar Diagnosis Kanker Paru. Jakarta: UI Press, 2017, pp. 127–168.
Silvestri GA, Pastis NJ, Tanner NT, et al. Clinical Aspects of Lung Cancer. In: Broaddus VC, Mason RJ, Murray JF, et al. (eds) Murray & Nadel's Textbook of Respiratory Medicine. Elsevier Saunders, pp. 940–964.
Paraschiv B, Diaconu CC, Toma CL, et al. Paraneoplastic Syndromes: The Way to an Early Diagnosis of Lung Cancer. Pneumologia 2015; 64: 14–19. [PubMed]
International Agency for Research on Cancer. Fact Sheets by Population, Incidence, Mortality, and 5-Year Prevalence: Both Sexes: Indonesia. Geneva, http://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf (2018).
Nakamura K, Ukawa S, Okada E, et al. Characteristics and Prognosis of Japanese Male and Female Lung Cancer Patients: The BioBank Japan Project. J Epidemiol 2017; 27: S49–S57. [PubMed]
Dewi AP. Kadar Procalcitonin pada Pasien Kanker Paru dengan Pneumonia. Universitas Indonesia, https://lib.ui.ac.id/detail?id=20481531&lokasi=lokal (2018).
Novariani R. Proporsi Kanker Paru dengan Riwayat Kanker pada Keluarga. Universitas Indonesia, https://lib.ui.ac.id/detail?id=20417080&lokasi=lokal (2015).
(WHO) WHO. Global Youth Tobacco Survey ("ŽGYTS)"Ž Indonesia Report, 2014. New Delhi, https://apps.who.int/iris/handle/10665/205148 (2015).
Athey VL, Walters SJ, Rogers TK. Symptoms at Lung Cancer Diagnosis are Associated with Major Differences in Prognosis. Thorax 2018; 73: 1177–1181. [PubMed]
Sanikini H, Yuan J-M, Butler LM, et al. Body Mass Index and Lung Cancer Risk: A Pooled Analysis based on Nested Case-Control Studies from Four Cohort Studies. BMC Cancer 2018; 18: 220. [PubMed]
Latimer KM, Mott TF. Lung Cancer: Diagnosis, Treatment Principles, and Screening. Am Fam Physician 2015; 91: 250–256. [PubMed]
Fukumoto K, Ito H, Matsuo K, et al. Cigarette Smoke Inhalation and Risk of Lung Cancer: A Case-Control Study in a Large Japanese Population. Eur J Cancer Prev 2015; 24: 195–200. [PubMed]
Zhang X, Wu L, Xu Y, et al. Trends in the Incidence Rate of Lung Cancer by Histological Type and Gender in Sichuan, China, 1995-2015: A Single-Center Retrospective Study. Thorac Cancer 2018; 9: 532–541. [PubMed]
Kong J, Xu F, He M, et al. The Incidence of Lung Cancer by Histological Type: A Population-Based Study in Tianjin, China during 1981-2005. Respirology 2014; 19: 1222–1228. [PubMed]
Baburao A, Narayanswamy H. Clinico-Pathological Profile and Haematological Abnormalities Associated with Lung Cancer in Bangalore, India. Asian Pac J Cancer Prev 2015; 16: 8235–8238. [PubMed]
Sembiring R, Hidajat H, Jusuf A, et al. Klasifikasi Histologis Kanker Paru. In: Jusuf A (ed) Dasar-Dasar Diagnosis Kanker Paru. Jakarta: UI Press, 2017, pp. 89–101.
Sagawa M, Sugawara T, Ishibashi N, et al. Efficacy of Low-Dose Computed Tomography Screening for Lung Cancer: The Current State of Evidence of Mortality Reduction. Surg Today 2017; 47: 783–788. [PubMed]
Nawa T, Fukui K, Nakayama T, et al. A Population-Based Cohort Study to Evaluate the Effectiveness of Lung Cancer Screening Using Low-Dose CT in Hitachi City, Japan. Jpn J Clin Oncol 2019; 49: 130–136. [PubMed]
Jusuf A, Wibawanto A, Icksan A, et al. Kanker Paru Jenis Karsinoma bukan Sel Kecil: Pedoman Diagnosis dan Penatalaksanaan di Indonesia. Jakarta, 2016.
Souilah S, Dermech N, Benbetka Y, et al. Anemia during Lung Cancer. 2018. Epub ahead of print 15 September 2018.
ZabÅ‚ocka-SÅ‚owiÅ„ska KA, Kosacka M, PorÄ™bska I, et al. The Usefulness of Routinely Used Malnutrition Screening Tools in Predicting Anemia in Lung Cancer Patients. Adv Clin Exp Med 2017; 26: 1383–1389. [PubMed]
Bacha S, Mejdoub El Fehri S, Habibech S, et al. Impact of Malnutrition in Advanced Non-Small Cell Lung Cancer. Tunis Med 2018; 96: 59–63. [PubMed]
Macciò A, Madeddu C, Gramignano G, et al. The Role of Inflammation, Iron, and Nutritional Status in Cancer-Related Anemia: Results of a Large, Prospective, Observational Study. Haematologica 2015; 100: 124–132. [PubMed]
Sbrana A, Torchio M, Comolli G, et al. Use of Procalcitonin in Clinical Oncology: A Literature Review. New Microbiol 2016; 39: 174–180. [PubMed]
Scheinpflug K, Schalk E, Grabert E, et al. Procalcitonin is Not Useful to Discriminate between Infectious and Non-Infectious CRP Elevation in Patients with Non-Small Cell Lung Cancer. Infection Control and Hospital Epidemiology 2015; 36: 1117–1118. [PubMed]
Avrillon V, Locatelli-Sanchez M, Folliet L, et al. Lung Cancer May Increase Serum Procalcitonin Level. Infect Disord Drug Targets 2015; 15: 57–63. [PubMed]
DurnaÅ› B, WÄ…tek M, Wollny T, et al. Utility of Blood Procalcitonin Concentration in the Management of Cancer Patients with Infections. Onco Targets Ther 2016; 9: 469–475. [PubMed]
Higuchi T, Omata F, Tsuchihashi K, et al. Current Cigarette Smoking is a Reversible Cause of Elevated White Blood Cell Count: Cross-Sectional and Longitudinal Studies. Prev Med Reports 2016; 4: 417–422. [PubMed]
Jameson JL, Longo DL. Paraneoplastic Syndromes: Endocrinologic/Hematologic. In: Jameson JL, Fauci AS, Kasper DL, et al. (eds) Harrison's Principles of Internal Medicine, 20e. New York, NY: McGraw-Hill Education, http://accessmedicine.mhmedical.com/content.aspx?aid=1160012181 (2018).
Abughanimeh O, Tahboub M, Abu Ghanimeh M. Metastatic Lung Adenocarcinoma Presenting with Hypereosinophilia. Cureus 2018; 10: e2866. [PubMed]
Pastis NJ, Tanner NT, Silvestri GA. Extrapulmonary Syndromes Associated with Lung Tumors. In: Grippi MA, Elias JA, Fishman JA, et al. (eds) Fishman's Pulmonary Diseases and Disorders. New York, NY: McGraw-Hill Education, http://accessmedicine.mhmedical.com/content.aspx?aid=1122367942 (2015).
Boddu P, Villlines D, Aklilu M. Paraneoplastic Leukocytosis and Thrombocytosis as Prognostic Biomarkers in Non-Small Cell Lung Cancer. Zhongguo Fei Ai Za Zhi 2016; 19: 725–730. [PubMed]
Khorana AA, Carrier M, Garcia DA, et al. Guidance for the Prevention and Treatment of Cancer-Associated Venous Thromboembolism. J Thromb Thrombolysis 2016; 41: 81–91. [PubMed]
Copyright (c) 2023 Andika Chandra Putra, Steven Jonathan, Wira Winardi, Elisna Syahruddin
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions.
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
4. The Creative Commons Attribution Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under "the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violation.
JR (